Generic Name: durvalumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Immunotherapy Medications

Company: AstraZeneca

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Imfinzi is a checkpoint inhiibtor approved for advanced or metastatic bladder (urothelial) cancer, inoperable non-small-cell lung cancer and extensive-stage small cell lung cancer.

General Info

Imfinzi is a monoclonal antibody used in cancer immunotherapy. It is a checkpoint inhibitor that blocks the PD-L1 protein on cancer cells or immune cells in tumors. PD-1 is an immune checkpoint on T cells that plays a role in regulating immune function. Some tumors can hijack PD-1 to turn off immune responses against them. Drugs that block the interaction between PD-1 and PD-L1, its binding partner, can release the brakes and restore T-cell activity.

Clinical trials showed that Imfinzi slows progression of bladder cancer and small-cell lung cancer. The CASPIAN trial showed adding Imfinzi to chemotherapy improves survival in people with extensive-stage small cell lung cancer. Imfinzi was first approved in 2017.


Dosing Info:

Imfinzi is administered as an intravenous infusion. The dosing regimen depends on the type of cancer being treated.

Side Effects

Common side effects include fatigue, weakness, cough, shortness of breath, upper respiratory tract infections, hair loss and skin rash. Checkpoint inhibitors can cause an overactive immune response that harms healthy organs and tissues. Serious immune-mediated side effects can affect almost any organ including the lungs (known as pneumonitis), liver, kidneys, intestines, skin and hormone-producing endocrine glands.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: March 30, 2020